Unlike current single (GLP-1) and dual (GLP-1/GIP) agonist compounds like Semaglutide and Tirzepatide , Retatrutide is a triple agonist compound targeting three hormone receptors instead of only one or two: GLP-1 (glucagon-like peptide-1) GIP (glucose-dependent insulinotropic polypeptide) GCG (glucagon receptor) According to a landmark clinical trial published in the New England Journal of Medicine , Retatrutide demonstrated significant weight reduction, up to 30%, in participants over a 48-week period, highlighting its potential as a next-generation metabolic peptide
What is the difference between medical weight loss and dieting
Who is a good candidate for the Comprehensive Weight Loss Program
Davis said that means compounded tirzepatide won't be completely eliminated in the U.S., but the scale of it will "certainly decrease." The legal battle between the FDA and the Outsourcing Facilities Association isn't over yet, however
Jaworecka K, Pojawa-Golab M, Otto-Buczkowska E, Reich A